Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DBVT DBV Technologies	$9.19 -0.3%	$9.24	$2.20 ▼ $12.78	$243.22M	-0.63	191,385 shs	12,742 shs
IMNM Immunome	$8.77 -0.2%	$8.61	$5.15 ▼ $16.81	$763.10M	1.94	869,000 shs	1.07 million shs
LENZ LENZ Therapeutics	$30.18 +0.2%	$28.58	$16.54 ▼ $38.93	$849.45M	0.42	191,084 shs	1.29 million shs
XERS Xeris Biopharma	$4.70 -0.8%	$4.63	$2.03 ▼ $6.07	$735.01M	0.71	2.02 million shs	4.69 million shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DBVT DBV Technologies	-0.27%	-2.29%	-1.76%	+48.15%	+93.80%
IMNM Immunome	-0.23%	+0.23%	+1.62%	+25.46%	-27.10%
LENZ LENZ Therapeutics	+0.23%	+0.80%	+5.12%	+17.71%	+77.11%
XERS Xeris Biopharma	-0.84%	+4.21%	-1.67%	-15.77%	+113.64%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DBVT DBV Technologies	3.6996 of 5 stars	4.4	3.0	0.0	2.7	2.5	0.6
IMNM Immunome	2.2006 of 5 stars	3.5	2.0	0.0	2.2	2.5	0.0
LENZ LENZ Therapeutics	1.3207 of 5 stars	3.6	0.0	0.0	2.2	0.8	0.0
XERS Xeris Biopharma	4.1697 of 5 stars	3.4	1.0	4.2	3.4	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DBVT DBV Technologies	2.80	Moderate Buy	$14.75	60.59% Upside
IMNM Immunome	3.00	Buy	$23.33	166.06% Upside
LENZ LENZ Therapeutics	3.17	Buy	$46.60	54.41% Upside
XERS Xeris Biopharma	2.83	Moderate Buy	$6.25	32.98% Upside

Current Analyst Ratings Breakdown

Latest DBVT, XERS, LENZ, and IMNM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	DBVT DBV Technologies	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/26/2025	DBVT DBV Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$21.00
5/29/2025	DBVT DBV Technologies	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sell	$7.25
5/27/2025	DBVT DBV Technologies	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
5/27/2025	DBVT DBV Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$15.00 ➝ $21.00
5/13/2025	IMNM Immunome	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$33.00 ➝ $21.00
5/9/2025	XERS Xeris Biopharma	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$6.00 ➝ $7.00
5/8/2025	LENZ LENZ Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$38.00 ➝ $38.00
5/5/2025	DBVT DBV Technologies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $16.00
5/1/2025	DBVT DBV Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$10.00 ➝ $15.00
4/16/2025	LENZ LENZ Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$38.00 ➝ $38.00

(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DBVT DBV Technologies	$4.15M	60.62	N/A	N/A	$1.42 per share	6.47
IMNM Immunome	$9.04M	84.41	N/A	N/A	$2.27 per share	3.86
LENZ LENZ Therapeutics	N/A	N/A	N/A	N/A	$7.42 per share	N/A
XERS Xeris Biopharma	$203.07M	3.62	N/A	N/A	($0.20) per share	-23.50

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DBVT DBV Technologies	-$113.92M	-$4.92	N/A	N/A	N/A	-3,249.99%	-278.24%	-140.54%	7/29/2025 (Estimated)
IMNM Immunome	-$292.96M	-$3.18	N/A	N/A	N/A	-1,875.21%	-71.65%	-60.36%	8/11/2025 (Estimated)
LENZ LENZ Therapeutics	-$49.77M	-$1.77	N/A	N/A	N/A	N/A	-23.74%	-22.65%	8/13/2025 (Estimated)
XERS Xeris Biopharma	-$54.84M	-$0.30	N/A	N/A	N/A	-20.25%	N/A	-12.07%	8/6/2025 (Estimated)

Latest DBVT, XERS, LENZ, and IMNM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	IMNM Immunome	-$0.66	-$0.52	+$0.14	-$0.52	$0.46 million	$2.93 million
5/8/2025	Q1 2025	XERS Xeris Biopharma	-$0.07	-$0.06	+$0.01	-$0.06	$57.61 million	$57.80 million
5/7/2025	Q1 2025	LENZ LENZ Therapeutics	-$0.55	-$0.53	+$0.02	-$0.53	N/A	N/A
4/11/2025	Q4 2024	DBVT DBV Technologies	N/A	-$1.10	N/A	-$1.10	N/A	$0.51 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DBVT DBV Technologies	N/A	N/A	N/A	N/A	N/A
IMNM Immunome	N/A	N/A	N/A	N/A	N/A
LENZ LENZ Therapeutics	N/A	N/A	N/A	N/A	N/A
XERS Xeris Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DBVT DBV Technologies	N/A	0.72	0.72
IMNM Immunome	N/A	10.49	10.49
LENZ LENZ Therapeutics	N/A	23.09	23.09
XERS Xeris Biopharma	N/A	1.72	1.17

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DBVT DBV Technologies	71.74%
IMNM Immunome	44.58%
LENZ LENZ Therapeutics	54.32%
XERS Xeris Biopharma	42.75%

Insider Ownership

Company	Insider Ownership
DBVT DBV Technologies	1.44%
IMNM Immunome	8.60%
LENZ LENZ Therapeutics	6.90%
XERS Xeris Biopharma	6.47%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DBVT DBV Technologies	80	27.39 million	27.00 million	Optionable
IMNM Immunome	40	87.01 million	79.53 million	Optionable
LENZ LENZ Therapeutics	110	28.15 million	26.20 million	N/A
XERS Xeris Biopharma	290	156.38 million	146.27 million	Optionable

DBVT, XERS, LENZ, and IMNM Headlines

Recent News About These Companies

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Consensus Rating of "Moderate Buy" from Analysts

June 28 at 3:27 AM | marketbeat.com

Xeris Biopharma: Great Numbers, Great Technologies, And Suitable For Long-Term Investing

June 18, 2025 | seekingalpha.com

Xeris Biopharma (NASDAQ:XERS) Stock Price Up 8.4% Following Insider Buying Activity

June 18, 2025 | americanbankingnews.com

Xeris Biopharma (NASDAQ:XERS) Trading Up 8.4% on Insider Buying Activity

June 17, 2025 | marketbeat.com

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Insider Kevin Mcculloch Buys 25,000 Shares

June 17, 2025 | insidertrades.com

Kevin Mcculloch Purchases 25,000 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Stock

June 16, 2025 | marketbeat.com

Leerink Partnrs Estimates Xeris Biopharma FY2025 Earnings

June 9, 2025 | marketbeat.com

Leerink Partnrs Cuts Earnings Estimates for Xeris Biopharma

June 6, 2025 | marketbeat.com

Xeris Biopharma touts ambitious growth plan, promising hypothyroidism drug

June 4, 2025 | chicagobusiness.comC

Mackenzie Financial Corp Buys 106,153 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

June 4, 2025 | marketbeat.com

Xeris Unveils Strategy for Long-Term Growth and Value Creation at 2025 Analyst & Investor Day

June 3, 2025 | finance.yahoo.com

Xeris Biopharma (NASDAQ:XERS) Shares Down 5.5% - Here's What Happened

June 3, 2025 | marketbeat.com

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Average Rating of "Moderate Buy" from Analysts

June 3, 2025 | marketbeat.com

Nuveen Asset Management LLC Acquires 228,380 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

June 1, 2025 | marketbeat.com

Millennium Management LLC Raises Stock Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

May 29, 2025 | marketbeat.com

BNP Paribas Financial Markets Acquires Shares of 100,012 Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

May 28, 2025 | marketbeat.com

Xeris Announces Details for Analyst & Investor Day

May 20, 2025 | businesswire.com

Xeris Biopharma Holdings, Inc. (XERS): Among the Unstoppable Growth Stocks to Invest in Now

May 12, 2025 | msn.com

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q1 2025 Earnings Call Transcript

May 10, 2025 | insidermonkey.com

Xeris Biopharma Holdings Inc (XERS) Q1 2025 Earnings Call Highlights: Record Revenue Growth and ...

May 9, 2025 | finance.yahoo.com

Xeris Biopharma Holdings, Inc. (XERS) Q1 2025 Earnings Call Transcript

May 8, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DBVT, XERS, LENZ, and IMNM Company Descriptions

DBV Technologies NASDAQ:DBVT

$9.18 -0.03 (-0.27%)

Closing price 06/27/2025 03:58 PM Eastern

Extended Trading

$9.18 0.00 (0.00%)

As of 06/27/2025 05:48 PM Eastern

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

Immunome NASDAQ:IMNM

$8.77 -0.02 (-0.23%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$8.72 -0.05 (-0.57%)

As of 06/27/2025 05:18 PM Eastern

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

LENZ Therapeutics NASDAQ:LENZ

$30.18 +0.07 (+0.23%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$30.26 +0.07 (+0.25%)

As of 06/27/2025 05:11 PM Eastern

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

Xeris Biopharma NASDAQ:XERS

$4.70 -0.04 (-0.84%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$4.68 -0.02 (-0.43%)

As of 06/27/2025 07:46 PM Eastern

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time